Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2008 /
Zoledronic acid may have anti-tumour properties

10th - 14th Dec 2008

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.03.09
Views: 13724
Rating:

Dr Robert Coleman - Professor of Medical Oncology, University of Sheffield

Early results of the AZURE (Adjuvant Zoledronic Acid to Reduce Recurrence) trial suggest that zoledronic acid may have antitumor properties when combined with chemotherapy. Treatment was linked with a reduction in tumor size (20.5 mm vs. 30 mm), an increase in the complete response rate (10.9 percent vs. 5.8 percent) and a decrease in the number of patients requiring mastectomy (65.3 percent vs. 77.9 percent). Speaking at the 2008 San Antonio Breast Cancer Symposium.

Categories:

Breast SABCS 2008

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation